drugset / Trial / NCT07164469
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Phase 2
Not yet recruiting
100 enrolled
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.
Timeline
- Start
- 2026-12-28
- Primary completion
- 2031-09-30
- Completion
- 2033-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD70.CAR NK Cells | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | Rimiducid | Other / unclassified | — | Intravenous |